Evidence map›Paper›PMID 37839874›Full record

ArticleInternal medicine (Tokyo, Japan)2023

Anti-Kv1.4 Antibody-positive Nivolumab-induced Myasthenia Gravis and Myositis Presenting with Bilateral Ptosis and Demonstrating Different Pathophysiologies.

Yuki Kitazaki, Osamu Yamamura, Kojiro Usui, Asako Ueno, Sayaka Sanada, Hirohito Sasaki, Yoshinori Endo, Soichi Enomoto, Masamichi Ikawa, Yasunari Nakamoto and 1 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yuki KitazakiSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan.
Osamu YamamuraSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan.
Kojiro UsuiSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan.
Asako UenoSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan.
Sayaka SanadaSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan.
Hirohito SasakiSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan.
Yoshinori EndoSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan.
Soichi EnomotoSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan.
Masamichi IkawaSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan.
Yasunari NakamotoSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan.
Tadanori HamanoSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan.
University of Fukui · JPFukui-ken Saiseikai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nivolumab blocks inhibitors of T-cell activation and restores antitumor immunity but promotes T-cell activity in host tissues by blocking inhibition of the T-cell function, resulting in immune-related adverse effects. We herein report an 80-year-old man presenting with nivolumab-related myasthenia gravis with anti-muscular voltage-gated potassium channel-complex (Kv1.4) antibodies. On day 29 after nivolumab administration, he simultaneously developed rapidly progressing right ptosis and left facial paralysis. Nivolumab administration was discontinued. He subsequently presented with bulbar paralysis, dyspnea, and muscle weakness and received intravenous immunoglobulin, methylprednisolone, and plasma exchange. The severity of nivolumab-related myasthenia gravis with anti-Kv1.4 antibodies presented with diverse clinical findings.

Indexed as

BlepharoptosisMyasthenia GravisMyositisAged, 80 and overHumansMaleMuscle WeaknessNivolumabNivolumabanti-muscular voltage-gated potassium channel antibodiesfacial paralysisimmune-related adverse eventmyasthenia gravisnivolumab

Identifiers

PMID37839874
PMCPMC10641203
OpenAlexW4387638003

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.